Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10541435rdf:typepubmed:Citationlld:pubmed
pubmed-article:10541435lifeskim:mentionsumls-concept:C0752312lld:lifeskim
pubmed-article:10541435lifeskim:mentionsumls-concept:C1155873lld:lifeskim
pubmed-article:10541435lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:10541435lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:10541435lifeskim:mentionsumls-concept:C0175668lld:lifeskim
pubmed-article:10541435lifeskim:mentionsumls-concept:C0073064lld:lifeskim
pubmed-article:10541435pubmed:issue10lld:pubmed
pubmed-article:10541435pubmed:dateCreated1999-11-22lld:pubmed
pubmed-article:10541435pubmed:abstractTextThe reovirus type 3 S1 gene product (type 3 hemagglutinin; HA3) is the viral protein responsible for binding to a mammalian cell-surface receptor. It has been shown that HA3 binding to its receptor inhibits cell growth, even in the continuous presence of serum mitogens. Here, receptor-mediated signal transduction leading to growth arrest was studied after binding with synthetic or recombinant ligands in the absence of viral infection. Receptor ligation caused rapid inactivation of p21(ras), a decrease in Raf phosphorylation and in mitogen-activated protein kinase (MAPK) enzymatic activity, and G1 cell cycle arrest. Transfection and expression of constitutively active v-Has-ras prevented the G1 arrest, indicating that inactivation of p21(ras) is causative. Interestingly, v-Has-ras expression also decreased the efficiency of reoviridae replication, suggesting that inactivation of p21(ras) signals is required at some step of the viral cycle. This study may define new mechanisms regulating cell growth and support the approach of using viral proteins to identify and study cellular receptors. Synthetic receptor ligands with antiproliferative properties may be useful in drug development with the aim of blocking mitosis.lld:pubmed
pubmed-article:10541435pubmed:languageenglld:pubmed
pubmed-article:10541435pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:citationSubsetIMlld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10541435pubmed:statusMEDLINElld:pubmed
pubmed-article:10541435pubmed:monthOctlld:pubmed
pubmed-article:10541435pubmed:issn1044-5498lld:pubmed
pubmed-article:10541435pubmed:authorpubmed-author:GreeneM IMIlld:pubmed
pubmed-article:10541435pubmed:authorpubmed-author:MacleodRRlld:pubmed
pubmed-article:10541435pubmed:authorpubmed-author:RubinD HDHlld:pubmed
pubmed-article:10541435pubmed:authorpubmed-author:ShenkNNlld:pubmed
pubmed-article:10541435pubmed:authorpubmed-author:SaragoviH UHUlld:pubmed
pubmed-article:10541435pubmed:authorpubmed-author:RebaiNNlld:pubmed
pubmed-article:10541435pubmed:authorpubmed-author:Di...lld:pubmed
pubmed-article:10541435pubmed:issnTypePrintlld:pubmed
pubmed-article:10541435pubmed:volume18lld:pubmed
pubmed-article:10541435pubmed:ownerNLMlld:pubmed
pubmed-article:10541435pubmed:authorsCompleteYlld:pubmed
pubmed-article:10541435pubmed:pagination763-70lld:pubmed
pubmed-article:10541435pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:meshHeadingpubmed-meshheading:10541435...lld:pubmed
pubmed-article:10541435pubmed:year1999lld:pubmed
pubmed-article:10541435pubmed:articleTitleA G1 cell cycle arrest induced by ligands of the reovirus type 3 receptor is secondary to inactivation of p21ras and mitogen-activated protein kinase.lld:pubmed
pubmed-article:10541435pubmed:affiliationDepartment of Pharmacology, McGill Cancer Center, McGill University, Montréal, Québec, Canada.lld:pubmed
pubmed-article:10541435pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10541435pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10541435lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10541435lld:pubmed